Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
J Infect Chemother ; 27(2): 250-255, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33060044

RESUMEN

INTRODUCTION: Nitrofurantoin is a well-established antibiotic, and is an important first-line oral treatment for uncomplicated urinary tract infections. However, little information is available with respect to its antibacterial activity in Japan, in vivo efficacy, or the in vivo biological cost of resistant strains. METHODS: We compared the susceptibility of six representative antibacterial agents-nitrofurantoin, sulfamethoxazole/trimethoprim, fosfomycin, mecillinam, ciprofloxacin, and cefdinir-against E. coli clinically isolated in Japan during 2017. We evaluated the in vivo efficacy of nitrofurantoin using a model of mouse urinary tract infection caused by ciprofloxacin resistant E. coli. We obtained nitrofurantoin resistant isolates through tests generating spontaneous mutations, and assessed the in vivo fitness of nitrofurantoin resistant isolates. RESULTS: The MIC90 of nitrofurantoin was 16 µg/mL, and was the lowest among the drugs tested. It was found that, in the mouse urinary tract infection model, 30 mg/kg and 100 mg/kg of nitrofurantoin reduced the count of viable bacterial cells in the kidney, while 100 mg/kg of ciprofloxacin did not. All spontaneous bacterial mutants resistant to nitrofurantoin had deletions in the nfsA gene, and we found that the resistant strain had lower growth in the mouse urinary tract infection model than in the parent strain. CONCLUSIONS: We demonstrated promising in vitro and in vivo activity of nitrofurantoin against E. coli clinical isolates in Japan, and lower in vivo fitness of the resistant strain of nitrofurantoin.


Asunto(s)
Infecciones por Escherichia coli , Infecciones Urinarias , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Escherichia coli/genética , Infecciones por Escherichia coli/tratamiento farmacológico , Humanos , Japón , Pruebas de Sensibilidad Microbiana , Nitrofurantoína/farmacología , Nitrofurantoína/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico
2.
Toxicol Sci ; 139(2): 466-78, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24743698

RESUMEN

The herbicide paraquat is an environmental factor that may be involved in the etiology of Parkinson's disease (PD). Systemic exposure of mice to paraquat causes a selective loss of dopaminergic neurons in the substantia nigra pars compacta, although paraquat is not selectively incorporated in dopaminergic neurons. Here, we report a contribution of endogenous dopamine to paraquat-induced dopaminergic cell death. Exposure of PC12 cells to paraquat (50µM) caused delayed toxicity from 36 h onward. A decline in intracellular dopamine content achieved by inhibiting tyrosine hydroxylase (TH), an enzyme for dopamine synthesis, conferred resistance to paraquat toxicity on dopaminergic cells. Paraquat increased the levels of cytosolic and vesicular dopamine, accompanied by transiently increased TH activity. Quinone derived from cytosolic dopamine conjugates with cysteine residues in functional proteins to form quinoproteins. Formation of quinoprotein was transiently increased early during exposure to paraquat. Furthermore, pretreatment with ascorbic acid, which suppressed the elevations of intracellular dopamine and quinoprotein, almost completely prevented paraquat toxicity. These results suggest that the elevation of cytosolic dopamine induced by paraquat participates in the vulnerability of dopaminergic cells to delayed toxicity through the formation of quinoproteins.


Asunto(s)
Dopamina/metabolismo , Herbicidas/toxicidad , Paraquat/toxicidad , Animales , Descarboxilasas de Aminoácido-L-Aromático/metabolismo , Western Blotting , Catecol O-Metiltransferasa/metabolismo , Técnicas de Cultivo de Célula , Supervivencia Celular/efectos de los fármacos , Vesículas Citoplasmáticas/efectos de los fármacos , Vesículas Citoplasmáticas/metabolismo , Citosol/efectos de los fármacos , Citosol/metabolismo , Inmunohistoquímica , Monoaminooxidasa/metabolismo , Células PC12 , Ratas , Tirosina 3-Monooxigenasa/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA